NASDAQ · XRAYHealthcareDental Equipment

DENTSPLY SIRONA financials

$8.98−3.23%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Q4 '24
Dec 31
Q3 '24
Sep 30
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$898.0M$880.0M$961.0M$904.0M$936.0M$879.0M$905.0M$951.0M$984.0M$953.0M$1.01B$947.0M
Gross profit$493.0M$427.0M$443.0M$441.0M$490.0M$466.0M$446.0M$495.0M$511.0M$506.0M$522.0M$495.0M
Gross margin54.9%48.5%46.1%48.8%52.4%53.0%49.3%52.1%51.9%53.1%51.6%52.3%
Operating income$82.0M-$35.0M-$139.0M-$218.0M-$128.0M$63.0M-$509.0M-$462.0M$50.0M$42.0M$73.0M-$236.0M
Net income$37.0M-$10.0M-$146.0M-$427.0M-$45.0M$20.0M-$430.0M-$494.0M-$4.0M$18.0M$67.0M-$266.0M
Net margin4.1%−1.1%−15.2%−47.2%−4.8%2.3%−47.5%−51.9%−0.4%1.9%6.6%−28.1%
Diluted EPS$0.18$-0.05$-0.73$-2.14$-0.22$0.10$-2.18$-2.46$-0.02$0.09$0.32$-1.25
EBITDA$169.0M$111.0M$113.0M$141.0M$199.0M$151.0M$91.0M$154.0M$157.0M$135.0M$70.0M$165.0M
Operating cash flow$99.0M$40.0M$101.0M$79.0M$48.0M$7.0M$87.0M$141.0M$208.0M$25.0M$160.0M$134.0M
Free cash flow$55.0M-$12.0M$60.0M$40.0M$16.0M-$12.0M$36.0M$98.0M$156.0M-$9.0M$120.0M$97.0M
Diluted shares200.5M199.9M199.0M199.5M199.3M199.8M197.7M201.0M205.6M208.5M208.6M211.8M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$239.0M$190.0M$326.0M$363.0M$359.0M$398.0M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$2.22B$2.24B$2.33B$2.40B$2.40B$2.33B
Total assets$5.20B$5.23B$5.43B$5.65B$6.07B$6.05B
Total liabilities$3.85B$3.91B$4.09B$4.17B$4.11B$4.04B
Shareholders' equity$1.35B$1.32B$1.34B$1.48B$1.96B$2.01B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology